Name:Pagluferal-1,2,3 (Pagluferalum-1,2,3)
Indications for use:
Mainly in epilepsy with grand tonic-clonic seizures.
Pharmacological action:
Due to the properties of its constituent components.
Pagluferalum-1,2,3 (Pagluferal-1,2,3) method of administration and doses:
Different ratios of ingredients in different variants of pagluferalum tablets make it possible to individually select doses. Start taking 1-2 tablets 1-2 times every day.
Pagluferalum-1,2,3 (Pagluferal-1,2,3) contraindications:
The drug is contraindicated in severe liver and kidney damage with impaired function, alcoholism, drug addiction, myasthenia gravis (muscle weakness). It should not be prescribed in the first 3 months. pregnancy (to avoid teratogenic effects /damaging effect on the fetus/) and women who are breastfeeding.
Pagluferalum-1,2,3 (Pagluferal-1,2,3) side effects:
Inhibition of the activity of the central nervous system, lowering blood pressure, allergic reactions (skin rash, etc.), changes in the blood count.
Release form:
Pagluferal 1, 2 and 3 tablets containing, respectively: phenobarbital – 0.025; 0.035 or 0.05 g, bromized – 0.1; 0.1 or 0.15 g, sodium caffeine benzoate – 0.0075; 0.0075 or 0.01 g, papaverine hydrochloride – 0.015; 0.015 or 0.02 g, calcium gluconate – 0.25 g, in orange glass jars, 40 pcs.
Additionally:
Combination product containing phenobarbital, bromisoval, sodium caffeine benzoate, papaverine hydrochloride, calcium gluconate.
Storage conditions:
List B. In a place protected from light.
Attention!
Before using the medication“Pagluferalum-1,2,3 (Pagluferal-1,2,3)” should be consulted with a doctor.
The instructions are provided solely for familiarization with “Pagluferalum-1,2,3 (Pagluferal-1,2,3) ».